Edwards Lifesciences To Present At Credit Suisse 2014 Healthcare Conference
Medtronic Profit, Sales Seen Rising in 2Q -- Earnings Preview
The firm is on track to meet our full-year estimates, and our $60 per share fair value estimate and wide moat rating are intact.
Ownership data provide a look at who else owns the company.
The information and opinions presented herein are not meant to be taken as investment advice. We do our best to make sure the information presented in this article is factual and correct, but Zacks cannot be held responsible for any losses incurred from investment transactions made based on ...